Fahim Ebrahimi

Fahim Ebrahimi is a Postdoctoral Researcher at Karolinska Institutet's Department of Medical Epidemiology and Biostatistics, working within Jonas Ludvigsson's Gastrointestinal Epidemiology research group. His research spans multiple disciplines including hepatology, gastroenterology, endocrinology, and epidemiology, with a particular focus on metabolic dysfunction-associated steatotic liver disease (MASLD), inflammatory bowel disease, and their systemic complications.

His primary research interests include:

• Gastrointestinal epidemiology and disease patterns
• MASLD/NAFLD progression and complications
• Inflammatory bowel disease and associated conditions
• Cardiovascular risks in metabolic and gastrointestinal disorders
• Maternal-fetal health outcomes related to liver disease

Dr. Ebrahimi's recent publications (2023-2025) demonstrate a strong focus on nationwide cohort studies examining the long-term consequences of MASLD, inflammatory bowel disease, and related conditions. His work frequently employs population-based methodologies to investigate connections between gastrointestinal diseases and systemic complications including cardiovascular events, cancer risk, and mortality. His research shows particular strength in multigenerational studies examining familial patterns of disease.

His scientific contributions include:

• Multiple publications in high-impact journals including Gastroenterology, Lancet Regional Health, and Journal of Clinical Endocrinology & Metabolism
• Research examining bidirectional disease associations (e.g., between microscopic colitis and primary sclerosing cholangitis)
• Studies on the impact of MASLD across multiple organ systems
• Investigations into maternal-fetal health outcomes related to liver disease

Dr. Ebrahimi has secured competitive research funding from the Swiss National Science Foundation and the Swiss Academy of Medical Sciences for projects including 'Characterization of Determinants of Disease Occurrence, Progression and Adverse Clinical Outcomes in Metabolic-Associated Fatty Liver Disease' and 'Effects of IL-1 Beta on the hypothalamic-pituitary-gonadal (HPG) axis in men with obesity and metabolic syndrome.'